We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

MICROBIOLOGICS INC.

Microbiologics is a biological products and services provider that partners with healthcare and life science laborato... read more Featured Products: More products

Download Mobile App





Microbiologics Introduces First SARS-CoV-2 RNA IVD CE Marked Control

By LabMedica International staff writers
Posted on 25 Mar 2020
Microbiologics, Inc. More...
(Saint Cloud, MN, USA) has launched a SARS-CoV-2 IVD control within its popular Helix Elite line of molecular controls to help accelerate COVID-19 assay development and increase access to testing. The new IVD product provides quality control measures for the development, verification, and validation of diagnostic tests, with the unmatched precision and convenience of the Helix Elite line.

Microbiologics partners with healthcare and life science laboratories, manufacturers and suppliers across the globe to co-create and provide biological control materials, assay services and consulting for microbiology, molecular diagnostics and virology.

Microbiologics’ SARS-CoV-2 Helix Elite control features a large RNA molecule that matches the sequence of the virus N gene (which codes for the nucleocapsid phosphoprotein found in the shell of the virus) and works with CDC-specified test components to generate positive PCR signals. The synthetic RNA control material is non-infectious and classified as BSL-1, remaining stable at room temperature to allow convenient shipping and storage. The Helix Elite SARS-CoV-2 IVD control is manufactured under ISO 13485 standards, and is designed for extended use and flexibility to match the hectic pace of high-volume testing. Microbiologics aims to continue developing resources for the global response to COVID-19, including IVD RNA controls with other gene sequences from the SARS-CoV-2 virus.

“With all the unknowns of this new coronavirus strain, third party IVD controls with the right genomic targets are more critical than ever,” said Marylou Gibson, Microbiologics’ Chief Virologist. “This new SARS-CoV-2 control comes with the proven quality of the Helix Elite product line to assure your test results.”

Related Links:
Microbiologics, Inc.


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Online QC Software
Acusera 24•7
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.